Shionogi & Co (TYO:4507) said 89% of HIV patients in a ViiV Healthcare study opted to switch from daily pills to long-acting injectable Cabenuva, according to a Thursday filing on the Tokyo Stock Exchange.

The Phase IIIb VOLITION trial, presented at the IAS 2025 conference, involved treatment-naïve adults who achieved rapid viral suppression with oral Dovato.

Most chose to switch to Cabenuva, citing convenience and reduced anxiety about missing doses.

ViiV is jointly owned by Shionogi, GlaxoSmithKline and Pfizer.